Skye Bioscience Inc (NASDAQ:SKYE)’s traded shares stood at 0.81 million during the last session, with the company’s beta value hitting 1.78. At the close of trading, the stock’s price was $3.72, to imply an increase of 4.79% or $0.17 in intraday trading. The SKYE share’s 52-week high remains $19.41, putting it -421.77% down since that peak but still an impressive 39.52% since price per share fell to its 52-week low of $2.25. The company has a valuation of $112.86M, with an average of 0.14 million shares in intraday trading volume over the past 10 days and average of 324.20K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Skye Bioscience Inc (SKYE), translating to a mean rating of 1.00. Of 3 analyst(s) looking at the stock, 0 analyst(s) give SKYE a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 3 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.29.
Skye Bioscience Inc (NASDAQ:SKYE) trade information
After registering a 4.79% upside in the last session, Skye Bioscience Inc (SKYE) has traded red over the past five days. The 5-day price performance for the stock is -17.15%, and -30.73% over 30 days. With these gigs, the year-to-date price performance is 36.76%. Short interest in Skye Bioscience Inc (NASDAQ:SKYE) saw shorts transact 1.99 million shares and set a 9.41 days time to cover.
The extremes give us $15 and $21 for target low and target high price respectively. As such, SKYE has been trading -464.52% off suggested target high and -303.23% from its likely low.
Skye Bioscience Inc (SKYE) estimates and forecasts
Looking at statistics comparing Skye Bioscience Inc share performance against respective industry, we note that the company has outperformed competitors. Skye Bioscience Inc (SKYE) shares are -66.00% down over the last 6 months, with its year-to-date growth rate higher than industry average at 82.12% against 17.50%.
SKYE Dividends
Skye Bioscience Inc has its next earnings report out in January. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Skye Bioscience Inc (NASDAQ:SKYE)’s Major holders
Skye Bioscience Inc insiders hold 1.32% of total outstanding shares, with institutional holders owning 86.08% of the shares at 87.23% float percentage. In total, 86.08% institutions holds shares in the company.
